Atopic Dermatitis

The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.

This approval announcement by Galderma follows the previous FDA approval of nemolizumab for prurigo nodularis.

This interim analysis highlights positive findings from the Measure Up 1 and 2 studies regarding upadacitinib for patients with atopic dermatitis.

These data provide insight into characteristics of those who choose to discontinue systemic therapies for eczema.

This assessment of dupilumab for pediatric and adult patients with moderate-to severe eczema treated for up to 5 years confirms the drug efficacy and safety across age groups.

These topline findings regarding MH004, or tofacitinib etocomil ointment 1.0%, demonstrated efficacy for this twice-daily pan-Jak inhibitor in adolescents and adults with eczema.

This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.

In this analysis in Thailand, video education’s impact on patient guardians’ knowledge was assessed with the aim of reducing eczema severity.

MJH Life Sciences, parent company of HCPLive, has acquired the RAD Annual Meeting, a premier CME-certified conference advancing dermatology knowledge and research.

These data on patients in Japan with eczema suggest there was sustained effectiveness in these patients’ clinical signs and in patient-reported outcomes.

In this analysis, patterns of global access to biologic drugs for patients with atopic dermatitis were explored among 50 countries.

New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.

More patients with atopic dermatitis on stapokibart than on placebo achieved ≥ 75% improvement in Eczema Area and Severity Index over 52 weeks.

This interview from Fall Clinical featured a discussion of new findings on upadacitinib (Rinvoq) for patients with atopic dermatitis.

This interview at the Fall Clinical Dermatology Conference features a discussion with Stein Gold regarding the open-label extension of the phase 3 ADORING trial regarding tapinarof.

Many with moderate-to-severe atopic dermatitis do not reach treatment targets in 12 months, underscoring a need for proactive management strategies.

Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.

This interview with Bunick highlighted the LEVEL UP phase 3b/4 trial findings regarding upadacitinib treatment of patients with atopic dermatitis.

In these data presented at the Fall Clinical Dermatology conference, population-based data on utilization and duration of systemic corticosteroid exposure was highlighted.

In this interview, Kwatra highlighted several key takeaways from his talks on prurigo nodularis, atopic dermatitis, and itch at the Fall Clinical Dermatology Conference.

These long-term extension trial data from ADORING 3 highlight tapinarof cream’s efficacy in adults and children aged 2 years and older with atopic dermatitis.

These data from the ADapt study, presented at Fall Clinical, suggest improvements among patients with eczema given lebrikizumab-lbkz who had been previously treated with dupilumab.

These data were presented at Fall Clinical, highlighting the reductions in Eczema Area and Severity Index scores and the overall long-term safety profile of tralokinumab-ldrm.

At the Fall Clinical Dermatology conference, Chovatiya presented on chronic hand eczema and facts about its pathophysiology, diagnosis, and management.